ImmunoGen partners with Takeda to commercialize Elahere in Japan

29 August 2023

US antibody-drug conjugates (ADCs) developer ImmunoGen (Nasdaq: IMGN) has entered into an exclusive collaboration with Takeda Pharmaceutical (TYO: 4502) to develop and commercialize Elahere (mirvetuximab soravtansine-gynx; MIRV) in Japan, with the news sending the firm’s shares up as much as 3% to $15.68 this morning

Subject to the terms of the agreement, Takeda will obtain an exclusive license in Japan to develop and commercialize MIRV in all indications. In return, Takeda said it will make a one-time upfront payment and an additional payment upon conversion of US Food and Drug Administration (FDA) accelerated approval of MIRV in platinum-resistant ovarian cancer to full approval totaling 5 billion yen ($34.5 million) to ImmunoGen. In addition, milestone payments based on achievement of regulatory and sales and royalties on sales may be payable.

This is the third licensing deal for ImmunoGen this year, adding to an agreements with Canada’s ImmunoBiochem Corp, and one with Vertex Pharmaceuticals (NYSE: VRTX) which could earn it around $350 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK